Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05009797

PROSPective Evaluation of Outcome After CatheTer Ablation in Atrial Fibrillation

PROSPective Evaluation of Outcome After CatheTer Ablation in Atrial Fibrillation : LONGITUDINAL STUDY OF PATIENTS UNDERGOING RADIOFREQUENCY ABLATION OF ATRIAL FIBRILLATION.

Status
Recruiting
Phase
Study type
Observational
Enrollment
750 (estimated)
Sponsor
University Hospital, Lille · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Atrial fibrillation ablation is the most common intervention performed worldwide. Up to 20 to 45% of patients show recurrence of AF within 12 month after catheter ablation, however its determinant are incompletely understood. The aim of the PROSPECT-AF study is to assess the predictors of AF recurrence within the 3 years following ablation using clinical variables and innovative biomarkers in a prospective cohort of 750 patients undergoing atrial fibrillation catheter ablation. The secondary aims are to assess the incidence of major adverse cardiovascular outcomes (MACE) and the incidence of major bleeding within the 3 years Wolfing catheter ablation.

Conditions

Interventions

TypeNameDescription
PROCEDUREatrial fibrillation catheter ablationThe ablation is performed under local anesthesia or general anesthesia. A transseptal puncture will be performed to access the left atrium. Pulmonary vein isolation will be performed as a first step. Additional lesions will be made at the discretion of the operators. Patients will receive anticoagulation for at least 3 months after the ablation. Treatment thereafter will be extended at the discretion of the treating physician.

Timeline

Start date
2023-02-16
Primary completion
2031-02-01
Completion
2031-02-01
First posted
2021-08-18
Last updated
2026-04-07

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT05009797. Inclusion in this directory is not an endorsement.